Inogen (NASDAQ:INGN) Releases Quarterly Earnings Results, Beats Expectations By $0.15 EPS

Inogen (NASDAQ:INGN) posted its earnings results on Tuesday. The medical technology company reported ($0.41) EPS for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.15, Zacks reports. Inogen had a negative return on equity of 27.38% and a negative net margin of 15.89%. Inogen updated its FY 2025 guidance to EPS and its Q1 2025 guidance to EPS.

Inogen Price Performance

Inogen stock traded down $0.32 during midday trading on Tuesday, reaching $9.52. The company had a trading volume of 354,528 shares, compared to its average volume of 265,333. Inogen has a 12-month low of $5.82 and a 12-month high of $13.33. The firm’s fifty day simple moving average is $10.19 and its 200-day simple moving average is $10.28. The company has a market capitalization of $226.75 million, a P/E ratio of -4.23 and a beta of 1.02.

Wall Street Analyst Weigh In

Several analysts have commented on the company. Needham & Company LLC reissued a “hold” rating on shares of Inogen in a report on Thursday, January 30th. StockNews.com raised shares of Inogen from a “hold” rating to a “buy” rating in a research note on Monday, February 10th.

About Inogen

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.